GAL-3 recently was introduced as a biomarker for the assessment of prognosis in patients with HF.1 Here we demonstrate that renal impairment is a major determinant of plasma GAL-3 in patients with or without HF. This evidence concerns the gene LGALS3 and hydrops fetalis.